{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:42:57Z","timestamp":1794660177653,"version":"4.9.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adoptive cell therapy with tumor-targeted T cells is a promising approach to cancer therapy. Enhanced clinical outcome using this approach requires conditioning regimens with total body irradiation, lymphodepleting chemotherapy, and\/or additional cytokine support. However, the need for prior conditioning precludes optimal application of this approach to a significant number of cancer patients intolerant to these regimens. Herein, we present preclinical studies demonstrating that treatment with CD19-specific, chimeric antigen receptor (CAR)\u2013modified T cells that are further modified to constitutively secrete IL-12 are able to safely eradicate established disease in the absence of prior conditioning. We demonstrate in a novel syngeneic tumor model that tumor elimination requires both CD4+ and CD8+ T-cell subsets, autocrine IL-12 stimulation, and subsequent IFN\u03b3 secretion by the CAR+ T cells. Importantly, IL-12\u2013secreting, tumor-targeted T cells acquire intrinsic resistance to T regulatory cell\u2013mediated inhibition. Based on these preclinical data, we anticipate that adoptive therapy using CAR-targeted T cells modified to secrete IL-12 will obviate or reduce the need for potentially hazardous conditioning regimens to achieve optimal antitumor responses in cancer patients.<\/jats:p>","DOI":"10.1182\/blood-2011-12-400044","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T03:12:36Z","timestamp":1329880356000},"page":"4133-4141","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":641,"title":["Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning"],"prefix":"10.1182","volume":"119","author":[{"given":"Hollie J.","family":"Pegram","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik G.","family":"Hayman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin H.","family":"Imperato","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Tedder","sequence":"additional","affiliation":[{"name":"Department of Immunology, Duke University, Durham, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"},{"name":"Center for Cell Engineering, and"},{"name":"Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"},{"name":"Center for Cell Engineering, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2019111808380773900_B1","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"95","key":"2019111808380773900_B2","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"18","key":"2019111808380773900_B3","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"32","key":"2019111808380773900_B4","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808380773900_B5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"issue":"18 pt 1","key":"2019111808380773900_B6","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111808380773900_B7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/mt.2011.1","article-title":"CARs on track in the clinic.","volume":"19","author":"Kohn","year":"2011","journal-title":"Mol Ther"},{"issue":"1","key":"2019111808380773900_B8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"issue":"20 pt 1","key":"2019111808380773900_B9","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111808380773900_B10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"issue":"6","key":"2019111808380773900_B11","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111808380773900_B12","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111808380773900_B13","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1128\/MCB.14.6.3884","article-title":"Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development.","volume":"14","author":"Zhou","year":"1994","journal-title":"Mol Cell Biol"},{"issue":"18","key":"2019111808380773900_B14","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1158\/1078-0432.CCR-06-0979","article-title":"Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.","volume":"12","author":"Ferrone","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2019111808380773900_B15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-59745-409-4_7","article-title":"Retroviral transduction of murine primary T lymphocytes.","volume":"506","author":"Lee","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2019111808380773900_B16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.neo.7900018","article-title":"Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.","volume":"1","author":"Gong","year":"1999","journal-title":"Neoplasia"},{"issue":"8","key":"2019111808380773900_B17","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","article-title":"In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"2019111808380773900_B18","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"issue":"27","key":"2019111808380773900_B19","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1182\/blood-2009-08-232967","article-title":"Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.","volume":"114","author":"James","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111808380773900_B20","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.4049\/jimmunol.1003317","article-title":"Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model.","volume":"186","author":"Lisiero","year":"2011","journal-title":"J Immunol"},{"issue":"19","key":"2019111808380773900_B21","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111808380773900_B22","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111808380773900_B23","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"issue":"7","key":"2019111808380773900_B24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"2 Pt 1","key":"2019111808380773900_B25","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","article-title":"Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.","volume":"13","author":"Bracci","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111808380773900_B26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"issue":"8","key":"2019111808380773900_B27","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI32205","article-title":"Microbial translocation augments the function of adoptively transferred self\/tumor-specific CD8+ T cells via TLR4 signaling.","volume":"117","author":"Paulos","year":"2007","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111808380773900_B28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity.","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2019111808380773900_B29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.20021910","article-title":"Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function.","volume":"197","author":"Curtsinger","year":"2003","journal-title":"J Exp Med"},{"issue":"7","key":"2019111808380773900_B30","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.4049\/jimmunol.175.7.4392","article-title":"Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis.","volume":"175","author":"Curtsinger","year":"2005","journal-title":"J Immunol"},{"issue":"10","key":"2019111808380773900_B31","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.4049\/jimmunol.177.10.6962","article-title":"Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector\/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.","volume":"177","author":"Kilinc","year":"2006","journal-title":"J Immunol"},{"issue":"22","key":"2019111808380773900_B32","doi-asserted-by":"crossref","first-page":"8700","DOI":"10.1158\/0008-5472.CAN-09-1145","article-title":"Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance.","volume":"69","author":"Cao","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"2019111808380773900_B33","first-page":"414","article-title":"Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12.","volume":"59","author":"Cavallo","year":"1999","journal-title":"Cancer Res"},{"issue":"4","key":"2019111808380773900_B34","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/mt.2010.295","article-title":"Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.","volume":"19","author":"Zhao","year":"2011","journal-title":"Mol Ther"},{"issue":"17","key":"2019111808380773900_B35","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-10-0735","article-title":"Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.","volume":"70","author":"Kerkar","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"2019111808380773900_B36","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111808380773900_B37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00002371-200101000-00011","article-title":"Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12.","volume":"24","author":"Gollob","year":"2001","journal-title":"J Immunother"},{"issue":"3","key":"2019111808380773900_B38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ygyno.2003.12.022","article-title":"A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.","volume":"92","author":"Wadler","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2019111808380773900_B39","first-page":"9","article-title":"Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.","volume":"5","author":"Robertson","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111808380773900_B40","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"issue":"8","key":"2019111808380773900_B41","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/1078-0432.CCR-03-0304","article-title":"Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes.","volume":"10","author":"van Herpen","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111808380773900_B42","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1172\/JCI58814","article-title":"IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.","volume":"121","author":"Kerkar","year":"2011","journal-title":"J Clin Invest"},{"issue":"17","key":"2019111808380773900_B43","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/18\/4133\/1352003\/zh801812004133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/18\/4133\/1352003\/zh801812004133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:04:52Z","timestamp":1574085892000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/18\/4133\/30054\/Tumortargeted-T-cells-modified-to-secrete-IL12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,3]]},"references-count":43,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2012,5,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-12-400044","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,3]]}}}